<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Car-T vs. Bispecifics for Lymphoma: Using the Evidence to Sequence Treatments

minute read

by Healio | January 17, 2024
placeholder

CU Cancer Center member Manali Kamdar, MD, associate professor of medicine-hematology at CU School of Medicine, outlined an evidence-guided approach to sequencing CAR-T and bispecific antibody treatments in this population.

Topics: Press Coverage

Comments